US Patent

US7553863 — Ultrapure 4-methylpyrazole

Composition of Matter · Assigned to Paladin Labs Barbados Inc · Expires 2027-06-30 · 1y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a novel process for producing ultrapure 4-methylpyrazole with specific impurity levels.

USPTO Abstract

Disclosed is an ultrapure 4-methylpyrazole containing less than 0.1% pyrazole and containing less than 10 ppm each of hydrazine and nitrobenzaldehyde. The ultrapure 4-methylpyrazole is prepared by a novel process so that less than 0.01% of ethylvinyl ether is present.

Drugs covered by this patent

Patent Metadata

Patent number
US7553863
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-06-30
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Paladin Labs Barbados Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.